OPHIREX, INC
Novel antivenin therapeutic for snakebite envenomation treatment
- Sector
- Biotech
- Headquarters
- Corte Madera, CA
- Latest Form D
- $16.5M, Mar 2022
- Total capital
- $64.4M
- Federal grants
- $1.7M
- 2 awards · 2018–2021
- Rank in peer group#126 of 326
- Private capital raised
- $16.5M
- 2 Form D · last Mar 2022
- 55 months since last filing
- Federal contracts
- $46.2M
- 6 awards · Defense
- Rank in Biotech#18 of 4373
- Granted patents
- 3
- 18 pending · first 2021
- Rank in peer group#45 of 326
Capital timeline
Latest events
- Federal contractDefense · Dha Ph II Seql Proposal H2S-0045, Title: Broad-spectrum Snakebite Antidote: Metalloprotease Inhibition To Improve Recovery Time Following Snakebite, Medical R & D Egs 23000510$1.3M
- Federal contractDefense · Follow On Phase III Research And Development SBIR For Project Titled, Broad-spectrum Snakebite Antidote: Oral Product Development And IV Clinical Study$23.4M
- Private capital raisedForm D · SEC · 2nd filing$16.5M
- Federal grantDefense · Phase II · Broad Spectrum Envenomation Treatment$1.5M
- Federal contractDefense · COVID-19 Dha 2018.1 SBIR Phase III Medical R&d Contract Proposal Titled: "targeting SPLA2 For Treatment Of Acute Respiratory Distress Syndrome (ards) Associated With SARS-COV-2" Log #19000053$9.9M
- Federal contractDefense · Army Medical Research And Development SBIR Phase III Contract Titled Advancement Of Advancement Broad-spectrum Snakebite Antidote.$9.4M
- Federal contractDefense · Dha SBIR Ph II Medical R&d Contract For Proposal No. H2-0440, Titled: "broad Spectrum Envenomation Treatment".$1.5M
- Offering registeredForm D · SEC · 1st filing$5M
Show 2 earlier federal awards
- Federal grantDefense · Phase I · Broad Spectrum Envenomation Treatment$149K
- Federal contractDefense · Igf::ot::igf Socom Baa Award Proposal Log SO150138 Field Antidote For Snake Bite$627K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
23months
from OPHIREX, INC’s first federal award to its first private round.
- First federal award · May 2017
- Defense · $627K
- First Form D · Mar 2019
- $5M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#126 · top 39%
- Granted patents#45 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Matthew LewinResearcherExecutive Officer, Director, PromoterLinked by 3 patents · $1.5M in grants as PI
- Curt R. LaBelleDirectorNamed in SEC Form D filings
- Derrick R. RossiDirectorNamed in SEC Form D filings
- Hans R. BishopDirectorNamed in SEC Form D filings
- Howard J. PienDirector, PromoterNamed in SEC Form D filings
- Jeremiah R. HarrisonDirectorNamed in SEC Form D filings
Show all 9 people
- Jerry J. HarrisonDirector, PromoterNamed in SEC Form D filings
- Nancy J. KochExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Timothy R. GarnettDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 21- GrantedEARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESISUSPTOUS 12,564,575
- GrantedPLA2 Inhibitors For Treatment Of Pathological Conditions Caused By Hymenoptera Envenomation, Such As Hemolysis, Cerebral Edema, And Acute Kidney InjuryUSPTOUS 12,383,531
- PendingUse Of SPLA2 Inhibitors To Treat Envenomation By Snakes And WaspsUSPTOApplication 19000226
Show all 21 patent records
- EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESISMar 3, 2026 · US 12,564,575Granted
- PLA2 Inhibitors For Treatment Of Pathological Conditions Caused By Hymenoptera Envenomation, Such As Hemolysis, Cerebral Edema, And Acute Kidney InjuryAug 12, 2025 · US 12,383,531Granted
- Use Of SPLA2 Inhibitors To Treat Envenomation By Snakes And WaspsApr 17, 2025 · Application 19000226Pending
- Use Of SPLA2 Inhibitors To Treat Hymenoptera Envenomation, Hemolysis, And Kidney Disease, And To Protect Blood From Osmotic FragilityApr 17, 2025 · Application 19000102Pending
- Compositions And Dosage Forms For Topical And Transdermal Delivery Of Actives And Methods Of UseNov 21, 2024 · Application 18703760Pending
- EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESISNov 24, 2022 · Application 17767173Pending
- Envenomation Therapies And Related Pharmaceutical Compositions, Systems And KitsMay 11, 2021 · US 11,000,506Granted
- PLA2 And Hmg-coa Inhibitors For Treatment Of Pathological Conditions Causing Hemolysis, Cerebral Edema, And Acute Kidney InjuryApplication PCTUS2017030436Pending
- Treatment Of Envenomation By Social And Swarming Hymenoptera Including Bees, Wasps, And Ants Using PLA2 InhibitorsApplication 62423693Pending
- Compositions And Their Use In Treatment MethodsApplication 62340075Pending
- Compositions And Their Use In Treatment MethodsApplication 62329611Pending
- Envenomation Therapies And Related Pharmaceutical Compositions, Systems And KitsApplication PCTUS2015061834Pending
- Envenomation Therapies And Related Pharmaceutical Compositions, Systems And KitsApplication 62243374Pending
- Envenomation Therapies And Related Pharmaceutical Compositions, Systems And KitsApplication 62131441Pending
- Administration Of Acetylcholinesterase Inhibitors To Mitigate Neurotoxin-induced Paralysis And Residual Neuromuscular BlockadeApplication PCTUS2013058640Pending
- Compositions And Dosage Forms For Topical And Transdermal Delivery Of Actives And Methods Of UseApplication PCTUS2022049321Pending
- Compositions And Dosage Forms For Topical And Transdermal Delivery Of Actives And Methods Of UseApplication 63277252Pending
- Early Management, Mitigation And Prevention Of Sepsis And Sepsis-like Syndromes, Including Neo-natal Ards Due To Infection, Injury Or IatrogenesisApplication PCTUS2020055709Pending
- EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESISApplication 63017966Pending
- EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES DUE TO INFECTION, INJURY or IATROGENESISApplication 62990020Pending
- EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES DUE TO INFECTION, INJURY or IATROGENESISApplication 62915209Pending
Related companies, and why
- 3D SystemsSimilar federal contract value in Biotech · $52.7M in contracts
- Cempra PharmaceuticalsSimilar federal contract value in Biotech · $52.5M in contracts
- Invirsa, Inc.Similar federal contract value in Biotech · $48M in contracts
- METABOLON, INC.Similar federal contract value in Biotech · $42M in contracts
- EITR BIOLOGICS, INC.Similar federal contract value in Biotech · $39.6M in contracts
- Sciome LLCSimilar federal contract value in Biotech · $39.3M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .